# Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

> **NCT01245179** · PHASE1 · RECRUITING · sponsor: **Abdullah Kutlar** · enrollment: 18 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** panobinostat

## Key facts

- **NCT ID:** NCT01245179
- **Lead sponsor:** Abdullah Kutlar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2010-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245179, "Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01245179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*